Vermillion Announces Patent for AD Biomarkers, Second Peer-Reviewed Paper on OVA1
May 27, 2011
Vermillion Announces Patent for AD Biomarkers, Second Peer-Reviewed Paper on OVA1
The patent covers the use of the proteins saposin D and Fam3c as biomarkers for Alzheimer's disease, while the paper, published this week in the online edition of Obstetrics & Gynecology, demonstrates that OVA1 has increased sensitivity and decreased specificity compared to conventional ovarian cancer tests.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Vermillion Posts $344,000 in Q2 Revenues, Including First Sales of OVA1 Test
August 13, 2010 / ProteoMonitor - Vermillion Posts $431K in Q1 Revenue, Anticipates Two Peer-Reviewed Articles on OVA1
May 13, 2011 / ProteoMonitor - Proteomics Firms Net More than $8.75M in IRS Funds; Bulk of Awards Aimed at Diagnostics Work
November 5, 2010 / ProteoMonitor - Vermillion Granted US Patent Supporting PAD Biomarker
September 17, 2010 / ProteoMonitor - Vermillion Receives Notice of Allowance for Patent on Alzheimer's Biomarkers
July 2, 2010 / ProteoMonitor